NO338679B1 - Kit(sett) for behandling av prostatasykdommer basert på lokal avlevering av aktive substanser - Google Patents

Kit(sett) for behandling av prostatasykdommer basert på lokal avlevering av aktive substanser Download PDF

Info

Publication number
NO338679B1
NO338679B1 NO20075490A NO20075490A NO338679B1 NO 338679 B1 NO338679 B1 NO 338679B1 NO 20075490 A NO20075490 A NO 20075490A NO 20075490 A NO20075490 A NO 20075490A NO 338679 B1 NO338679 B1 NO 338679B1
Authority
NO
Norway
Prior art keywords
prostate
drug
treatment
component
kit according
Prior art date
Application number
NO20075490A
Other languages
English (en)
Norwegian (no)
Other versions
NO20075490L (no
Inventor
Hans Lennernäs
Bo Lennernäs
Jonas Hugosson
Niklas Axén
Original Assignee
Lidds Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds Ab filed Critical Lidds Ab
Publication of NO20075490L publication Critical patent/NO20075490L/no
Publication of NO338679B1 publication Critical patent/NO338679B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20075490A 2005-03-31 2007-10-30 Kit(sett) for behandling av prostatasykdommer basert på lokal avlevering av aktive substanser NO338679B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Publications (2)

Publication Number Publication Date
NO20075490L NO20075490L (no) 2008-01-02
NO338679B1 true NO338679B1 (no) 2016-09-26

Family

ID=35044589

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075490A NO338679B1 (no) 2005-03-31 2007-10-30 Kit(sett) for behandling av prostatasykdommer basert på lokal avlevering av aktive substanser

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC7.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC7.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140014294A (cg-RX-API-DMAC7.html)
CN (1) CN101160116B (cg-RX-API-DMAC7.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602776C (cg-RX-API-DMAC7.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC7.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC7.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC7.html)
IL (1) IL185690A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011908A (cg-RX-API-DMAC7.html)
NO (1) NO338679B1 (cg-RX-API-DMAC7.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC7.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016209A2 (en) * 1996-10-16 1998-04-23 Etex Corporation Bioceramic compositions
US5795330A (en) * 1996-10-10 1998-08-18 Etex Corporation Mixing device
WO1999016423A1 (en) * 1997-10-01 1999-04-08 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
WO2004084857A1 (en) * 2003-03-27 2004-10-07 Mpathy Medical Devices Limited Medicament delivery device and a method of medicament delivery
WO2004098560A1 (en) * 2003-05-05 2004-11-18 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
WO2005039537A1 (en) * 2003-10-22 2005-05-06 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795330A (en) * 1996-10-10 1998-08-18 Etex Corporation Mixing device
WO1998016209A2 (en) * 1996-10-16 1998-04-23 Etex Corporation Bioceramic compositions
WO1999016423A1 (en) * 1997-10-01 1999-04-08 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
WO2004084857A1 (en) * 2003-03-27 2004-10-07 Mpathy Medical Devices Limited Medicament delivery device and a method of medicament delivery
WO2004098560A1 (en) * 2003-05-05 2004-11-18 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
WO2005039537A1 (en) * 2003-10-22 2005-05-06 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery

Also Published As

Publication number Publication date
EP1865924B1 (en) 2015-12-09
RU2007140243A (ru) 2009-05-10
US8936809B2 (en) 2015-01-20
JP2013067639A (ja) 2013-04-18
WO2006103112A3 (en) 2006-12-21
NO20075490L (no) 2008-01-02
AU2006228675B2 (en) 2012-05-17
KR20080002776A (ko) 2008-01-04
EP1865924A2 (en) 2007-12-19
DK1865924T3 (en) 2016-02-29
WO2006103112A2 (en) 2006-10-05
ZA200708066B (en) 2016-07-27
CN101160116A (zh) 2008-04-09
US20080286205A1 (en) 2008-11-20
PL1865924T3 (pl) 2016-06-30
CN101160116B (zh) 2011-12-07
JP2008534546A (ja) 2008-08-28
HUE026158T2 (en) 2016-05-30
MX2007011908A (es) 2008-02-07
CA2602776C (en) 2013-10-22
JP5635231B2 (ja) 2014-12-03
RU2404747C2 (ru) 2010-11-27
CA2602776A1 (en) 2006-10-05
KR20140014294A (ko) 2014-02-05
ES2557988T3 (es) 2016-02-01
KR101380402B1 (ko) 2014-04-02
AU2006228675A1 (en) 2006-10-05
IL185690A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
US8936809B2 (en) Method for treating prostate diseases based on local delivery of active substances
JP6740497B2 (ja) 癌を治療するための方法及び組成物
EP1250138B1 (en) Fulvestrant formulation
JP6938462B2 (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
KR20090060306A (ko) 비타민 d 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
Lundgren Progestins in Breast Cancer Treatment: A Reveiw
Moszczyńska et al. Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma–case series and literature review
JP5302300B2 (ja) アンスラサイクリンの医薬組成物
RU2325160C1 (ru) Средство для лечения рака предстательной железы и профилактики его рецидива
US20250040935A1 (en) Fabrication of radiopaque resorbable hydrogel beads via microfluidics for catheter embolization applications
Hussain et al. P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)